IL158342A0 - Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides - Google Patents

Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides

Info

Publication number
IL158342A0
IL158342A0 IL15834202A IL15834202A IL158342A0 IL 158342 A0 IL158342 A0 IL 158342A0 IL 15834202 A IL15834202 A IL 15834202A IL 15834202 A IL15834202 A IL 15834202A IL 158342 A0 IL158342 A0 IL 158342A0
Authority
IL
Israel
Prior art keywords
hla
prolamine
restricted
binding
methods
Prior art date
Application number
IL15834202A
Other languages
English (en)
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of IL158342A0 publication Critical patent/IL158342A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15834202A 2001-04-12 2002-04-11 Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides IL158342A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01201377 2001-04-12
EP01204383 2001-11-16
PCT/NL2002/000235 WO2002083722A2 (en) 2001-04-12 2002-04-11 Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides

Publications (1)

Publication Number Publication Date
IL158342A0 true IL158342A0 (en) 2004-05-12

Family

ID=26076879

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15834202A IL158342A0 (en) 2001-04-12 2002-04-11 Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides

Country Status (7)

Country Link
US (1) US20040241161A1 (es)
EP (1) EP1377604B1 (es)
CA (1) CA2443886A1 (es)
IL (1) IL158342A0 (es)
MX (1) MXPA03009313A (es)
NO (1) NO20034588L (es)
WO (1) WO2002083722A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
AU2003215272B2 (en) * 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
DK1563300T3 (da) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
AU2005237287B2 (en) 2004-04-28 2011-08-11 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
EP1612558A1 (en) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US8092794B2 (en) * 2006-03-15 2012-01-10 Isocell Pharma S.A. Pharmaceutical compositions comprising SODs and prolamine based peptide fragments
WO2008090126A1 (de) * 2007-01-22 2008-07-31 N-Zyme Biotec Gmbh Getränke für zöliakiepatienten und gluten/gliadin-sensitive personen und verfahren zur herstellung
EP2659901B1 (en) * 2008-04-21 2015-01-21 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
EP2367561B1 (en) 2008-11-30 2015-05-20 Immusant, Inc. Compositions and methods for treatment of celiac disease
FR2942409B1 (fr) * 2009-02-20 2013-07-26 Natacha Voillot Composition pharmaceutique pour la prevention des avortements a repetition.
EP2673292A4 (en) * 2011-02-08 2014-05-21 Phadia Ab WHEAT ANTIGENES AND PEPTIDES FOR DIAGNOSIS OF WHEAT SENSITIVITY
CN104254777B (zh) 2011-12-05 2016-08-24 伯乐实验室公司 重组脱酰胺化麦醇溶蛋白抗原
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
EP3585818A4 (en) * 2017-02-27 2020-12-23 Chugai Seiyaku Kabushiki Kaisha ANTI-HLA-DQ2.5 / 8 ANTIBODIES AND ITS USE FOR THE TREATMENT OF C LIATIC DISEASE
PE20231208A1 (es) 2020-09-18 2023-08-17 Chugai Pharmaceutical Co Ltd Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement

Also Published As

Publication number Publication date
EP1377604A2 (en) 2004-01-07
NO20034588L (no) 2003-12-10
MXPA03009313A (es) 2004-11-12
WO2002083722A3 (en) 2003-02-06
NO20034588D0 (no) 2003-10-13
EP1377604B1 (en) 2014-12-31
CA2443886A1 (en) 2002-10-24
US20040241161A1 (en) 2004-12-02
WO2002083722A2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
IL158342A0 (en) Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
EP1420796A4 (en) ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE
PL363322A1 (en) Combination therapy using anti-egfr antibodies and anti-hormonal agents
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
IL160001A0 (en) Peptide based multimeric targeted contrast agents and methods for the preparation thereof
EP1391212A4 (en) ORAL PREPARATIONS AND MEDIA FOR ORAL PREPARATIONS
AU2002254224A1 (en) Apparatus and methods for capture of medical agents
EP1416884A4 (en) DISTRIBUTION OF AGENTS WITH THERAPEUTIC PROPERTIES
EP1377232A4 (en) OCULAR DEVICES FOR DELIVERY OF THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SUCH DEVICES
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
PL365780A1 (en) Promyostatin peptides and methods of using same
EP1372739A4 (en) STABILIZED THERAPEUTIC AND IMAGING AGENTS
HUP0401863A3 (en) Amino acid-copolymers for suppression of autoimmune diseases, and methods of use
AU2002364699A8 (en) Receptors and membrane-associated proteins
EP1501352A4 (en) METHOD AND COMPOSITIONS FOR PROTRACTED ACTIVE SUBSTANCE
EP1406631A4 (en) DOPAMINE RECEPTOR LIGANDS AND CORRESPONDING THERAPEUTIC METHODS
AU2002309970A8 (en) Receptors and membrane-associated proteins
AU2003222225A8 (en) Receptors and membrane-associated proteins
GB0325624D0 (en) Use of microparticles for antigen delivery
AU2002326910A1 (en) Receptors and membrane-associated proteins
AU2002253716A1 (en) Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
AU2002360790A8 (en) Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
EP1315737A4 (en) ORTHOLOGY OF HUMAN RECIPES AND USE METHOD
CA98995S (en) Base portion of an air-purifying device
EP1406921A4 (en) HYPOGLYCAEMIC PEPTIDES AND METHOD FOR USE THEREOF